Top

Published in:

01-03-2014 | Clinical

Concomitant resistance and early-breast cancer: should we change treatment strategies?

Authors: Carlos M. Galmarini, Olivier Tredan, Felipe C. Galmarini

Published in: Cancer and Metastasis Reviews | Issue 1/2014

Abstract

The dynamics of disease recurrence shows a bimodal pattern with a fairly broad dominant peak at about 1.5–2 years after surgery followed by a second peak at about 5 years. Nowadays, this clinical pattern is explained by assuming that primary breast tumours as well as their metastases have phases of both arrested (tumour dormancy) and active Gompertzian growth. Tumour dormancy at metastatic sites is currently ascribed to biological particularities of local tissue microenvironments that inhibit the growth of tumour cells. However, in some patients, tumour dormancy appears to also depend on the direct interplay between the primary tumour and those metastases, a biological phenomenon called “concomitant resistance”. Concomitant resistance is related to three biological processes: concomitant immunity, tumour-induced angiogenesis and athrepsia. Concomitant resistance can explain the bimodal relapse pattern of breast cancer patients as well as many other clinical phenomena such as the better clinical outcome among patients surgically treated during the putative early luteal phase, or the worse clinical outcome of African-American premenopausal women. Any therapeutic interventions (even surgery) can affect concomitant resistance with the potential to induce a worse as well as a better clinical outcome. This should be taken into account when planning new treatment strategies.

Fisher, B., Anderson, S., Redmond, C. K., Wolmark, N., Wickerham, D. L., & Cronin, W. M. (1995). Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer. The New England Journal of Medicine, 333(22), 1456–1461.PubMedCrossRef

Veronesi, U., Saccozzi, R., Del Vecchio, M., Banfi, A., Clemente, C., De Lena, M., et al. (1981). Comparing radical mastectomy with quadrantectomy, axillary dissection, and radiotherapy in patients with small cancers of the breast. The New England Journal of Medicine, 305(1), 6–11.PubMedCrossRef

Olson, J. A., Jr., McCall, L. M., Beitsch, P., Whitworth, P. W., Reintgen, D. S., Blumencranz, P. W., et al. (2008). Impact of immediate versus delayed axillary node dissection on surgical outcomes in breast cancer patients with positive sentinel nodes: results from American College of Surgeons Oncology Group Trials Z0010 and Z0011. Journal of Clinical Oncology, 26(21), 3530–3535.PubMedCrossRef

Peto, R., Davies, C., Godwin, J., Gray, R., Pan, H. C., Clarke, M., et al. (2012). Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet, 379(9814), 432–444.PubMedCrossRef

Rachet, B., Maringe, C., Nur, U., Quaresma, M., Shah, A., Woods, L. M., et al. (2009). Population-based cancer survival trends in England and Wales up to 2007: an assessment of the NHS cancer plan for England. The Lancet Oncology, 10(4), 351–369.PubMedCrossRef

Bloom, H. J. G. (1964). The natural history of untreated breast cancer. Annals of the New York Academy of Sciences, 114, 747–754.CrossRef

Demicheli, R., Retsky, M. W., Hrushesky, W. J., & Baum, M. (2007). Tumor dormancy and surgery-driven interruption of dormancy in breast cancer: learning from failures. Nature Clinical Practice Oncology, 4(12), 699–710.PubMedCrossRef

Karrison, T. G., Ferguson, D. J., & Meier, P. (1999). Dormancy of mammary carcinoma after mastectomy. Journal of the National Cancer Institute, 91(1), 80–85.PubMedCrossRef

Jerez, J. M., Franco, L., Alba, E., Llombart-Cussac, A., Lluch, A., Ribelles, N., et al. (2005). Improvement of breast cancer relapse prediction in high risk intervals using artificial neural networks. Breast Cancer Research and Treatment, 94(3), 265–272.PubMedCrossRef

10.

Sant, M., Gatta, G., Micheli, A., Verdecchia, A., Capocaccia, R., Crosignani, P., et al. (1991). Survival and age at diagnosis of breast cancer in a population-based cancer registry. European Journal of Cancer, 27(8), 981–984.PubMedCrossRef

11.

Baum, M., & Badwe, R. A. (1994). Does surgery influence the natural history of breast cancer? In H. Wise & H. J. Johnson (Eds.), Breast cancer: Controversies in management (pp. 61–69). Armonk, NY: Futura.

12.

Yakovlev, A. Y., Tsodikov, A. D., Boucher, K., & Kerber, R. (1999). The shape of the hazard function in breast carcinoma: curability of the disease revisited. Cancer, 85(8), 1789–1798.PubMedCrossRef

13.

Gao, F., Tan, S. B., Machin, D., & Wong, N. S. (2007). Confirmation of double-peaked time distribution of mortality among Asian breast cancer patients in a population-based study. Breast Cancer Research, 9(2), R21.PubMedCentralPubMedCrossRef

14.

Retsky, M., Demicheli, R., & Hrushesky, W. (2001). Premenopausal status accelerates relapse in node positive breast cancer: hypothesis links angiogenesis, screening controversy. Breast Cancer Research and Treatment, 65(3), 217–224.PubMedCrossRef

15.

Crowe, J. P., Jr., Gordon, N. H., Antunez, A. R., Shenk, R. R., Hubay, C. A., & Shuck, J. M. (1991). Local-regional breast cancer recurrence following mastectomy. Archives of Surgery, 126(4), 429–432.PubMedCrossRef

16.

Fortin, A., Larochelle, M., Laverdiere, J., Lavertu, S., & Tremblay, D. (1999). Local failure is responsible for the decrease in survival for patients with breast cancer treated with conservative surgery and postoperative radiotherapy. Journal of Clinical Oncology, 17(1), 101–109.PubMed

17.

Saphner, T., Tormey, D. C., & Gray, R. (1996). Annual hazard rates of recurrence for breast cancer after primary therapy. Journal of Clinical Oncology, 14(10), 2738–2746.PubMed

18.

Jatoi, I., Tsimelzon, A., Weiss, H., Clark, G. M., & Hilsenbeck, S. G. (2005). Hazard rates of recurrence following diagnosis of primary breast cancer. Breast Cancer Research and Treatment, 89(2), 173–178.PubMedCrossRef

19.

Gasparini, G., Biganzoli, E., Bonoldi, E., Morabito, A., Fanelli, M., & Boracchi, P. (2001). Angiogenesis sustains tumor dormancy in patients with breast cancer treated with adjuvant chemotherapy. Breast Cancer Research and Treatment, 65(1), 71–75.PubMedCrossRef

20.

Ripley, R. M., Harris, A. L., & Tarassenko, L. (2004). Non-linear survival analysis using neural networks. Statistics in Medicine, 23(5), 825–842.PubMedCrossRef

21.

Demicheli, R., Valagussa, P., & Bonadonna, G. (2002). Double-peaked time distribution of mortality for breast cancer patients undergoing mastectomy. Breast Cancer Research and Treatment, 75(2), 127–134.PubMedCrossRef

22.

Demicheli, R., Miceli, R., Brambilla, C., Ferrari, L., Moliterni, A., Zambetti, M., et al. (1999). Comparative analysis of breast cancer recurrence risk for patients receiving or not receiving adjuvant cyclophosphamide, methotrexate, fluorouracil (CMF). Data supporting the occurrence of ‘cures’. Breast Cancer Research and Treatment, 53(3), 209–215.PubMedCrossRef

23.

Demicheli, R., Miceli, R., Moliterni, A., Zambetti, M., Hrushesky, W. J., Retsky, M. W., et al. (2005). Breast cancer recurrence dynamics following adjuvant CMF is consistent with tumor dormancy and mastectomy-driven acceleration of the metastatic process. Annals of Oncology, 16(9), 1449–1457.PubMedCrossRef

24.

Norton, L., & Simon, R. (1977). Tumor size, sensitivity to therapy, and design of treatment schedules. Cancer Treatment Reports, 61(7), 1307–1317.PubMed

25.

Wiedswang, G., Borgen, E., Karesen, R., Kvalheim, G., Nesland, J. M., Qvist, H., et al. (2003). Detection of isolated tumor cells in bone marrow is an independent prognostic factor in breast cancer. Journal of Clinical Oncology, 21(18), 3469–3478.PubMedCrossRef

26.

Wiedswang, G., Borgen, E., Karesen, R., Qvist, H., Janbu, J., Kvalheim, G., et al. (2004). Isolated tumor cells in bone marrow 3 years after diagnosis in disease-free breast cancer patients predict unfavorable clinical outcome. Clinical Cancer Research, 10(16), 5342–5348.PubMedCrossRef

27.

Diel, I. J., Kaufmann, M., Costa, S. D., Holle, R., von Minckwitz, G., Solomayer, E. F., et al. (1996). Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status. Journal of the National Cancer Institute, 88(22), 1652–1658.PubMedCrossRef

28.

Gebauer, G., Fehm, T., Merkle, E., Beck, E. P., Lang, N., & Jager, W. (2001). Epithelial cells in bone marrow of breast cancer patients at time of primary surgery: clinical outcome during long-term follow-up. Journal of Clinical Oncology, 19(16), 3669–3674.PubMed

29.

Cote, R. J., Rosen, P. P., Lesser, M. L., Old, L. J., & Osborne, M. P. (1991). Prediction of early relapse in patients with operable breast cancer by detection of occult bone marrow micrometastases. Journal of Clinical Oncology, 9(10), 1749–1756.PubMed

30.

Mansi, J. L., Easton, D., Berger, U., Gazet, J. C., Ford, H. T., Dearnaley, D., et al. (1991). Bone marrow micrometastases in primary breast cancer: prognostic significance after 6 years’ follow-up. European Journal of Cancer, 27(12), 1552–1555.PubMedCrossRef

31.

Becker, S., Becker-Pergola, G., Wallwiener, D., Solomayer, E. F., & Fehm, T. (2006). Detection of cytokeratin-positive cells in the bone marrow of breast cancer patients undergoing adjuvant therapy. Breast Cancer Research and Treatment, 97(1), 91–96.PubMedCrossRef

32.

Braun, S., Kentenich, C., Janni, W., Hepp, F., de Waal, J., Willgeroth, F., et al. (2000). Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high-risk breast cancer patients. Journal of Clinical Oncology, 18(1), 80–86.PubMed

33.

Janni, W., Rack, B., Schindlbeck, C., Strobl, B., Rjosk, D., Braun, S., et al. (2005). The persistence of isolated tumor cells in bone marrow from patients with breast carcinoma predicts an increased risk for recurrence. Cancer, 103(5), 884–891.PubMedCrossRef

34.

Meng, S., Tripathy, D., Frenkel, E. P., Shete, S., Naftalis, E. Z., Huth, J. F., et al. (2004). Circulating tumor cells in patients with breast cancer dormancy. Clinical Cancer Research, 10(24), 8152–8162.PubMedCrossRef

35.

Bidard, F. C., Fehm, T., Ignatiadis, M., Smerage, J. B., Alix-Panabieres, C., Janni, W., et al. (2013). Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials. Cancer and Metastasis Reviews, 32(1–2), 179–188.PubMedCentralPubMedCrossRef

36.

Ruggiero, R. A., Bruzzo, J., Chiarella, P., Bustuoabad, O. D., Meiss, R. P., & Pasqualini, C. D. (2012). Concomitant tumor resistance: the role of tyrosine isomers in the mechanisms of metastases control. Cancer Research, 72(5), 1043–1050.PubMedCrossRef

37.

Franco, M., Bustuoabad, O. D., di Gianni, P. D., Goldman, A., Pasqualini, C. D., & Ruggiero, R. A. (1996). A serum-mediated mechanism for concomitant resistance shared by immunogenic and non-immunogenic murine tumours. British Journal of Cancer, 74(2), 178–186.PubMedCentralPubMedCrossRef

38.

North, R. J. (1984). The murine antitumor immune response and its therapeutic manipulation. Advances in Immunology, 35, 89–155.PubMedCrossRef

39.

Quesnel, B. (2008). Tumor dormancy and immunoescape. APMIS, 116(7–8), 685–694.PubMedCrossRef

40.

Nagaraj, S., & Gabrilovich, D. I. (2008). Tumor escape mechanism governed by myeloid-derived suppressor cells. Cancer Research, 68(8), 2561–2563.PubMedCrossRef

41.

Rabinovich, G. A., Gabrilovich, D., & Sotomayor, E. M. (2007). Immunosuppressive strategies that are mediated by tumor cells. Annual Review of Immunology, 25, 267–296.PubMedCentralPubMedCrossRef

42.

O'Reilly, M. S., Holmgren, L., Shing, Y., Chen, C., Rosenthal, R. A., Moses, M., et al. (1994). Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell, 79(2), 315–328.PubMedCrossRef

43.

Ruggiero, R. A., Bustuoabad, O. D., Cramer, P., Bonfil, R. D., & Pasqualini, C. D. (1990). Correlation between seric antitumor activity and concomitant resistance in mice bearing nonimmunogenic tumors. Cancer Research, 50(22), 7159–7165.PubMed

44.

Ruggiero, R. A., Bruzzo, J., Chiarella, P., di Gianni, P., Isturiz, M. A., Linskens, S., et al. (2011). Tyrosine isomers mediate the classical phenomenon of concomitant tumor resistance. Cancer Research, 71(22), 7113–7124.PubMedCrossRef

45.

Gorelik, E. (1983). Concomitant tumor immunity and the resistance to a second tumor challenge. Advances in Cancer Research, 39, 71–120.PubMedCrossRef

46.

Kusmartsev, S., & Gabrilovich, D. I. (2006). Role of immature myeloid cells in mechanisms of immune evasion in cancer. Cancer Immunology, Immunotherapy, 55(3), 237–245.PubMedCentralPubMedCrossRef

47.

Yu, P., Rowley, D. A., Fu, Y. X., & Schreiber, H. (2006). The role of stroma in immune recognition and destruction of well-established solid tumors. Current Opinion in Immunology, 18(2), 226–231.PubMedCrossRef

48.

Baker, D. G., Masterson, T. M., Pace, R., Constable, W. C., & Wanebo, H. (1989). The influence of the surgical wound on local tumor recurrence. Surgery, 106(3), 525–532.PubMed

49.

Hofer, S. O., Shrayer, D., Reichner, J. S., Hoekstra, H. J., & Wanebo, H. J. (1998). Wound-induced tumor progression: a probable role in recurrence after tumor resection. Archives of Surgery, 133(4), 383–389.PubMedCrossRef

50.

Decker, D., Schondorf, M., Bidlingmaier, F., Hirner, A., & von Ruecker, A. A. (1996). Surgical stress induces a shift in the type-1/type-2 T-helper cell balance, suggesting down-regulation of cell-mediated and up-regulation of antibody-mediated immunity commensurate to the trauma. Surgery, 119(3), 316–325.PubMedCrossRef

51.

Hansbrough, J. F., Bender, E. M., Zapata-Sirvent, R., & Anderson, J. (1984). Altered helper and suppressor lymphocyte populations in surgical patients. A measure of postoperative immunosuppression. American Journal of Surgery, 148(3), 303–307.PubMedCrossRef

52.

Hormbrey, E., Han, C., Roberts, A., McGrouther, D. A., & Harris, A. L. (2003). The relationship of human wound vascular endothelial growth factor (VEGF) after breast cancer surgery to circulating VEGF and angiogenesis. Clinical Cancer Research, 9(12), 4332–4339.PubMed

53.

Tagliabue, E., Agresti, R., Carcangiu, M. L., Ghirelli, C., Morelli, D., Campiglio, M., et al. (2003). Role of HER2 in wound-induced breast carcinoma proliferation. Lancet, 362(9383), 527–533.PubMedCrossRef

54.

Wu, F. P., Hoekman, K., Meijer, S., & Cuesta, M. A. (2003). VEGF and endostatin levels in wound fluid and plasma after breast surgery. Angiogenesis, 6(4), 255–257.PubMedCrossRef

55.

Ali, S., & Lazennec, G. (2007). Chemokines: novel targets for breast cancer metastasis. Cancer and Metastasis Reviews, 26(3–4), 401–420.PubMedCentralPubMedCrossRef

56.

Snyder, G. L., & Greenberg, S. (2010). Effect of anaesthetic technique and other perioperative factors on cancer recurrence. British Journal of Anaesthesia, 105(2), 106–115.PubMedCrossRef

57.

Coffey, J. C., Wang, J. H., Smith, M. J., Bouchier-Hayes, D., Cotter, T. G., & Redmond, H. P. (2003). Excisional surgery for cancer cure: therapy at a cost. The Lancet Oncology, 4(12), 760–768.PubMedCrossRef

58.

Hrushesky, W. J. (2000). Rhythmic menstrual cycle modulation of breast cancer biology. Journal of Surgical Oncology, 74(3), 238–241.PubMedCrossRef

59.

Veronesi, U., Luini, A., Mariani, L., Del Vecchio, M., Alvez, D., Andreoli, C., et al. (1994). Effect of menstrual phase on surgical treatment of breast cancer. Lancet, 343(8912), 1545–1547.PubMedCrossRef

60.

Jones, B., & Russo, J. (1987). Influence of steroid hormones on the growth fraction of human breast carcinomas. American Journal of Clinical Pathology, 88(2), 132–138.PubMed

61.

Heer, K., Kumar, H., Speirs, V., Greenman, J., Drew, P. J., Fox, J. N., et al. (1998). Vascular endothelial growth factor in premenopausal women–indicator of the best time for breast cancer surgery? British Journal of Cancer, 78(9), 1203–1207.PubMedCentralPubMedCrossRef

62.

Hrushesky, W. J., Gruber, S. A., Sothern, R. B., Hoffman, R. A., Lakatua, D., Carlson, A., et al. (1988). Natural killer cell activity: age, estrous- and circadian-stage dependence and inverse correlation with metastatic potential. Journal of the National Cancer Institute, 80(15), 1232–1237.PubMedCrossRef

63.

Carey, L. A., Perou, C. M., Livasy, C. A., Dressler, L. G., Cowan, D., Conway, K., et al. (2006). Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA, 295(21), 2492–2502.PubMedCrossRef

64.

Chlebowski, R. T., Chen, Z., Anderson, G. L., Rohan, T., Aragaki, A., Lane, D., et al. (2005). Ethnicity and breast cancer: factors influencing differences in incidence and outcome. Journal of the National Cancer Institute, 97(6), 439–448.PubMedCrossRef

65.

McDaniel, S. M., Rumer, K. K., Biroc, S. L., Metz, R. P., Singh, M., Porter, W., et al. (2006). Remodeling of the mammary microenvironment after lactation promotes breast tumor cell metastasis. The American Journal of Pathology, 168(2), 608–620.PubMedCentralPubMedCrossRef

66.

Schedin, P. (2006). Pregnancy-associated breast cancer and metastasis. Nature Reviews Cancer, 6(4), 281–291.PubMedCrossRef

67.

Dent, R., Trudeau, M., Pritchard, K. I., Hanna, W. M., Kahn, H. K., Sawka, C. A., et al. (2007). Triple-negative breast cancer: clinical features and patterns of recurrence. Clinical Cancer Research, 13(15 Pt 1), 4429–4434.PubMedCrossRef

68.

Carey, L. A. (2011). Directed therapy of subtypes of triple-negative breast cancer. The Oncologist, 16(Suppl 1), 71–78.PubMedCrossRef

69.

Bauer, K. R., Brown, M., Cress, R. D., Parise, C. A., & Caggiano, V. (2007). Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer, 109(9), 1721–1728.PubMedCrossRef

70.

Lianidou, E. S., Markou, A., & Strati, A. (2012). Molecular characterization of circulating tumor cells in breast cancer: challenges and promises for individualized cancer treatment. Cancer and Metastasis Reviews, 31(3–4), 663–671.PubMedCrossRef

71.

Fehm, T., Hoffmann, O., Aktas, B., Becker, S., Solomayer, E. F., Wallwiener, D., et al. (2009). Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells. Breast Cancer Research, 11(4), R59.PubMedCentralPubMedCrossRef

72.

Aktas, B., Muller, V., Tewes, M., Zeitz, J., Kasimir-Bauer, S., Loehberg, C. R., et al. (2011). Comparison of estrogen and progesterone receptor status of circulating tumor cells and the primary tumor in metastatic breast cancer patients. Gynecologic Oncology, 122(2), 356–360.PubMedCrossRef

73.

Kushi, L. H., Byers, T., Doyle, C., Bandera, E. V., McCullough, M., McTiernan, A., et al. (2006). American Cancer Society Guidelines on Nutrition and Physical Activity for cancer prevention: reducing the risk of cancer with healthy food choices and physical activity. CA: A Cancer Journal for Clinicians, 56(5), 254–281. quiz 313-254.

74.

Ursin, G., Bernstein, L., Wang, Y., Lord, S. J., Deapen, D., Liff, J. M., et al. (2004). Reproductive factors and risk of breast carcinoma in a study of white and African-American women. Cancer, 101(2), 353–362.PubMedCrossRef

75.

Breasted, J. H. (1930). The Edwin Smith Surgical Papyrus. Chicago: The University of Chicago Press.

76.

Chakrabarti, J., Kenny, F. S., Syed, B. M., Robertson, J. F., Blamey, R. W., & Cheung, K. L. (2011). A randomised trial of mastectomy only versus tamoxifen for treating elderly patients with operable primary breast cancer-final results at 20-year follow-up. Critical Reviews in Oncology/Hematology, 78(3), 260–264.PubMedCrossRef

77.

Hirai, T., Matsumoto, H., Kubota, H., & Yamaguchi, Y. (2013). Regulating surgical oncotaxis to improve the outcomes in cancer patients. Surg Today, in press

78.

Bonadonna, G., Zambetti, M., & Valagussa, P. (1989). Adjuvant chemotherapy for node-negative breast cancer patients. Recent Results in Cancer Research, 115, 175–179.PubMedCrossRef

79.

Castiglione-Gertsch, M., Tattersall, M., Hacking, A., Goldhirsch, A., Gudgeon, A., Gelber, R. D., et al. (1997). Retreating recurrent breast cancer with the same CMF-containing regimen used as adjuvant therapy. The International Breast Cancer Study Group. European Journal of Cancer, 33(14), 2321–2325.PubMedCrossRef

80.

Valagussa, P., Brambilla, C., Zambetti, M., & Bonadonna, G. (1989). Salvage treatments in relapsing resectable breast cancer. Recent Results in Cancer Research, 115, 69–76.PubMedCrossRef

81.

Galmarini, D., Galmarini, C. M., & Galmarini, F. C. (2012). Cancer chemotherapy: A critical analysis of its 60 years of history. Critical Reviews in Oncology/Hematology, 84(2), 181–199.PubMedCrossRef

82.

Pasquier, E., Kavallaris, M., & Andre, N. (2010). Metronomic chemotherapy: New rationale for new directions. Nature Reviews. Clinical Oncology, 7(8), 455–465.PubMedCrossRef

83.

Kerbel, R. S. (2011). Reappraising antiangiogenic therapy for breast cancer. Breast, 20(Suppl 3), S56–60.PubMedCrossRef

84.

Luster, A. D. (1998). Chemokines–chemotactic cytokines that mediate inflammation. The New England Journal of Medicine, 338(7), 436–445.PubMedCrossRef

85.

Retsky, M. W., Hrushesky, W. J., & Gukas, I. D. (2009). Hypothesis: Primary antiangiogenic method proposed to treat early stage breast cancer. BMC Cancer, 9, 7.PubMedCentralPubMedCrossRef

86.

Murphy, P. M., Baggiolini, M., Charo, I. F., Hebert, C. A., Horuk, R., Matsushima, K., et al. (2000). International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacological Reviews, 52(1), 145–176.PubMed

87.

Singh, J. K., Farnie, G., Bundred, N. J., Simoes, B. M., Shergill, A., Landberg, G., et al. (2013). Targeting CXCR1/2 significantly reduces breast cancer stem cell activity and increases the efficacy of inhibiting HER2 via HER2-dependent and -independent mechanisms. Clinical Cancer Research, 19(3), 643–656.PubMedCrossRef

88.

Kiderlen, M., de Glas, N. A., Bastiaannet, E., Engels, C. C., van de Water, W., de Craen, A. J., et al. (2013). Diabetes in relation to breast cancer relapse and all-cause mortality in elderly breast cancer patients: a FOCUS study analysis. Annals of Oncology, 24, 3011–3016

89.

Niraula, S., Dowling, R. J., Ennis, M., Chang, M. C., Done, S. J., Hood, N., et al. (2012). Metformin in early breast cancer: A prospective window of opportunity neoadjuvant study. Breast Cancer Research and Treatment, 135(3), 821–830.PubMedCrossRef

90.

Siclari, V. A., Guise, T. A., & Chirgwin, J. M. (2006). Molecular interactions between breast cancer cells and the bone microenvironment drive skeletal metastases. Cancer and Metastasis Reviews, 25(4), 621–633.PubMedCrossRef

91.

Winter, M. C., & Coleman, R. E. (2013). Bisphosphonates in the adjuvant treatment of breast cancer. Clinical Oncology (Royal College of Radiologists), 25(2), 135–145.CrossRef

92.

Fehm, T., Zwirner, M., Wallwiener, D., Seeger, H., & Neubauer, H. (2012). Antitumor activity of zoledronic acid in primary breast cancer cells determined by the ATP tumor chemosensitivity assay. BMC Cancer, 12, 308.PubMedCentralPubMedCrossRef

93.

Misso, G., Porru, M., Stoppacciaro, A., Castellano, M., De Cicco, F., Leonetti, C., et al. (2012). Evaluation of the in vitro and in vivo antiangiogenic effects of denosumab and zoledronic acid. Cancer Biology and Therapy, 13(14), 1491–1500.PubMedCentralPubMedCrossRef

94.

Giovannini, M., Aldrighetti, D., Zucchinelli, P., Belli, C., & Villa, E. (2010). Antiangiogenic strategies in breast cancer management. Critical Reviews in Oncology/Hematology, 76(1), 13–35.PubMedCrossRef

95.

Amadori, D., Aglietta, M., Alessi, B., Gianni, L., Ibrahim, T., Farina, G., et al. (2013). Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): A phase 3, open-label, randomised, non-inferiority trial. The Lancet Oncology, 14(7), 663–670.PubMedCrossRef

96.

Dedes, P. G., Kanakis, I., Gialeli, C., Theocharis, A. D., Tsegenidis, T., Kletsas, D., et al. (2013). Preclinical evaluation of zoledronate using an in vitro mimetic cellular model for breast cancer metastatic bone disease. Biochimica et Biophysica Acta, 1830(6), 3625–3634.PubMedCrossRef

97.

Paterson, A. H., Anderson, S. J., Lembersky, B. C., Fehrenbacher, L., Falkson, C. I., King, K. M., et al. (2012). Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): A multicentre, placebo-controlled, randomised trial. The Lancet Oncology, 13(7), 734–742.PubMedCrossRef

98.

Gottschalk, A., Sharma, S., Ford, J., Durieux, M. E., & Tiouririne, M. (2010). Review article: The role of the perioperative period in recurrence after cancer surgery. Anesthesia and Analgesia, 110(6), 1636–1643.PubMedCrossRef

99.

Forget, P., Vandenhende, J., Berliere, M., Machiels, J. P., Nussbaum, B., Legrand, C., et al. (2010). Do intraoperative analgesics influence breast cancer recurrence after mastectomy? A retrospective analysis. Anesthesia and Analgesia, 110(6), 1630–1635.PubMedCrossRef

100.

Retsky, M., Rogers, R., Demicheli, R., Hrushesky, W. J., Gukas, I., Vaidya, J. S., et al. (2012). NSAID analgesic ketorolac used perioperatively may suppress early breast cancer relapse: Particular relevance to triple negative subgroup. Breast Cancer Research and Treatment, 134(2), 881–888.PubMedCrossRef

101.

Howe, L. R. (2007). Inflammation and breast cancer. Cyclooxygenase/prostaglandin signaling and breast cancer. Breast Cancer Res, 9(4), 210.PubMedCentralPubMedCrossRef

102.

Singh, B., Berry, J. A., Vincent, L. E., & Lucci, A. (2006). Involvement of IL-8 in COX-2-mediated bone metastases from breast cancer. The Journal of Surgical Research, 134(1), 44–51.PubMedCrossRef

103.

Singh, B., & Lucci, A. (2002). Role of cyclooxygenase-2 in breast cancer. The Journal of Surgical Research, 108(1), 173–179.PubMedCrossRef

104.

Bendre, M. S., Montague, D. C., Peery, T., Akel, N. S., Gaddy, D., & Suva, L. J. (2003). Interleukin-8 stimulation of osteoclastogenesis and bone resorption is a mechanism for the increased osteolysis of metastatic bone disease. Bone, 33(1), 28–37.PubMedCrossRef

105.

Falandry, C., Canney, P. A., Freyer, G., & Dirix, L. Y. (2009). Role of combination therapy with aromatase and cyclooxygenase-2 inhibitors in patients with metastatic breast cancer. Annals of Oncology, 20(4), 615–620.PubMedCrossRef

106.

Lustberg, M. B., Povoski, S. P., Zhao, W., Ziegler, R. M., Sugimoto, Y., Ruppert, A. S., et al. (2011). Phase II trial of neoadjuvant exemestane in combination with celecoxib in postmenopausal women who have breast cancer. Clinical Breast Cancer, 11(4), 221–227.PubMedCentralPubMedCrossRef

107.

Perroud, H. A., Rico, M. J., Alasino, C. M., Queralt, F., Mainetti, L. E., Pezzotto, S. M., et al. (2013). Safety and therapeutic effect of metronomic chemotherapy with cyclophosphamide and celecoxib in advanced breast cancer patients. Future Oncology, 9(3), 451–462.PubMedCrossRef

108.

Roh, J. L., Sung, M. W., & Kim, K. H. (2005). Suppression of accelerated tumor growth in surgical wounds by celecoxib and indomethacin. Head and Neck, 27(4), 326–332.PubMedCrossRef

109.

Zhou, D., Papayannis, I., Mackenzie, G. G., Alston, N., Ouyang, N., Huang, L., et al. (2013). The anticancer effect of phospho-tyrosol-indomethacin (MPI-621), a novel phosphoderivative of indomethacin: in vitro and in vivo studies. Carcinogenesis, 34(4), 943–951.PubMedCentralPubMedCrossRef

110.

DiDonato, J. A., Mercurio, F., & Karin, M. (2012). NF-kappaB and the link between inflammation and cancer. Immunology Reviews, 246(1), 379–400.CrossRef

111.

Wu, J. T., & Kral, J. G. (2005). The NF-kappaB/IkappaB signaling system: A molecular target in breast cancer therapy. The Journal of Surgical Research, 123(1), 158–169.PubMedCrossRef

112.

Watanabe, M. A., Oda, J. M., Amarante, M. K., & Cesar Voltarelli, J. (2010). Regulatory T cells and breast cancer: Implications for immunopathogenesis. Cancer and Metastasis Reviews, 29(4), 569–579.PubMedCrossRef

113.

DeNardo, D. G., & Coussens, L. M. (2007). Inflammation and breast cancer. Balancing immune response: Crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Res, 9(4), 212.PubMedCentralPubMedCrossRef

114.

Wang, H. Y., & Wang, R. F. (2007). Regulatory T cells and cancer. Current Opinion in Immunology, 19(2), 217–223.PubMedCrossRef

115.

Thornton, A. M., & Shevach, E. M. (1998). CD4 + CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. The Journal of Experimental Medicine, 188(2), 287–296.PubMedCentralPubMedCrossRef

116.

Tarabichi, M., Antoniou, A., Saiselet, M., Pita, J. M., Andry, G., Dumont, J. E., et al. (2013). Systems biology of cancer: Entropy, disorder, and selection-driven evolution to independence, invasion and “swarm intelligence”. Cancer Metastasis Reviews, 32, 403–421.

117.

Whiteside, T. L. (2006). Immune suppression in cancer: Effects on immune cells, mechanisms and future therapeutic intervention. Seminars in Cancer Biology, 16(1), 3–15.PubMedCrossRef

118.

Bates, G. J., Fox, S. B., Han, C., Leek, R. D., Garcia, J. F., Harris, A. L., et al. (2006). Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. Journal of Clinical Oncology, 24(34), 5373–5380.PubMedCrossRef

119.

Ghebeh, H., Barhoush, E., Tulbah, A., Elkum, N., Al-Tweigeri, T., & Dermime, S. (2008). FOXP3+ Tregs and B7-H1+/PD-1+ T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: Implication for immunotherapy. BMC Cancer, 8, 57.PubMedCentralPubMedCrossRef

120.

Ohara, M., Yamaguchi, Y., Matsuura, K., Murakami, S., Arihiro, K., & Okada, M. (2009). Possible involvement of regulatory T cells in tumor onset and progression in primary breast cancer. Cancer Immunology, Immunotherapy, 58(3), 441–447.PubMedCrossRef

121.

Zhou, X., Bailey-Bucktrout, S., Jeker, L. T., & Bluestone, J. A. (2009). Plasticity of CD4(+) FoxP3(+) T cells. Current Opinion in Immunology, 21(3), 281–285.PubMedCentralPubMedCrossRef

122.

Alam, S. M., Clark, J. S., George, W. D., & Campbell, A. M. (1993). Altered lymphocyte populations in tumour invaded nodes of breast cancer patients. Immunology Letters, 35(3), 229–234.PubMedCrossRef

123.

Nakamura, R., Sakakibara, M., Nagashima, T., Sangai, T., Arai, M., Fujimori, T., et al. (2009). Accumulation of regulatory T cells in sentinel lymph nodes is a prognostic predictor in patients with node-negative breast cancer. European Journal of Cancer, 45(12), 2123–2131.PubMedCrossRef

124.

Matsuura, K., Yamaguchi, Y., Osaki, A., Ohara, M., Okita, R., Emi, A., et al. (2009). FOXP3 expression of micrometastasis-positive sentinel nodes in breast cancer patients. Oncology Reports, 22(5), 1181–1187.PubMedCrossRef

125.

Hasan, A., Ghebeh, H., Lehe, C., Ahmad, R., & Dermime, S. (2011). Therapeutic targeting of B7-H1 in breast cancer. Expert Opinion on Therapeutic Targets, 15(10), 1211–1225.PubMedCrossRef

126.

Emens, L. A. (2012). Breast cancer immunobiology driving immunotherapy: Vaccines and immune checkpoint blockade. Expert Review of Anticancer Therapy, 12(12), 1597–1611.PubMedCentralPubMedCrossRef

127.

Kroemer, G., Galluzzi, L., Kepp, O., & Zitvogel, L. (2013). Immunogenic cell death in cancer therapy. Annual Review of Immunology, 31, 51–72.PubMedCrossRef

128.

Denkert, C., Darb-Esfahani, S., Loibl, S., Anagnostopoulos, I., & Johrens, K. (2011). Anti-cancer immune response mechanisms in neoadjuvant and targeted therapy. Seminars in Immunopathology, 33(4), 341–351.PubMedCrossRef

129.

Beano, A., Signorino, E., Evangelista, A., Brusa, D., Mistrangelo, M., Polimeni, M. A., et al. (2008). Correlation between NK function and response to trastuzumab in metastatic breast cancer patients. Journal of Translational Medicine, 6, 25.PubMedCentralPubMedCrossRef

130.

Demicheli, R., Valagussa, P., & Bonadonna, G. (2001). Does surgery modify growth kinetics of breast cancer micrometastases? British Journal of Cancer, 85(4), 490–492.PubMedCentralPubMedCrossRef

Title: Concomitant resistance and early-breast cancer: should we change treatment strategies?
Authors: Carlos M. Galmarini
Olivier Tredan
Felipe C. Galmarini
Publication date: 01-03-2014
Publisher: Springer US
Published in: Cancer and Metastasis Reviews / Issue 1/2014
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-013-9449-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2014

Emerging evidence for CHFR as a cancer biomarker: from tumor biology to precision medicine

Gastrointestinal neuroendocrine tumors (NETs): new diagnostic and therapeutic challenges

Pancreatic NETs: where do we stand now?

The promise of sonodynamic therapy

Adoptive immunotherapy of metastatic breast cancer: present and future

Molecular biology of neuroendocrine tumors: from pathways to biomarkers and targets

Keynote webinar | Spotlight on antibody–drug conjugates in cancer